Thursday - March 5, 2026
Sanofi and Regeneron's Dupixent Approved in the US as the First and Only Medicine for Allergic Fungal Rhinosinusitis
February 25, 2026
PARIS, France, Feb. 25 -- Sanofi, a life sciences company, issued the following news release:

* * *

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

* Approval in adults and children aged 6 years and older supported by phase 3 study demon . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products